Effect of a new calcium antagonist, nilvadipine, on variant angina pectoris evaluated by 24-hour Holter electrocardiography.

Abstract

The clinical effect of nilvadipine, a new calcium antagonist, was investigated in a single blind trial in 19 patients with variant angina pectoris. The efficacy of the drug was evaluated on the basis of frequency of anginal attacks and Holter electrocardiographic findings during observation periods and during two treatment periods when the drug was given in doses of 4 mg twice a day or 4 mg 3 times a day. The frequency of anginal attacks and the consumption of sublingual nitroglycerin tablets decreased significantly in both treatment periods in comparison with those in the observation period before treatment, but in the observation period after treatment tended to increase in comparison with those during the second treatment period. The frequency and duration of ST-segment elevation and the maximum ST-segment elevation confirmed by Holter electrocardiography also improved significantly in both treatment periods, compared with those in the observation period before treatment. Our findings show that nilvadipine is effective for variant angina pectoris at doses of 4 mg twice a day.

• Authors: H Kishida, S Toyama, T Yanaga, K Suzuki
• Journal: Japanese heart journal (Jpn Heart J) Vol. 29 Issue 6 Pg. 781-93 (Nov 1988) ISSN: 0021-4868 [Print] Japan
• PMID: 3071619 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)

Chemical References

• Calcium Channel Blockers
• nilvadipine
• Nifedipine

Topics

• Angina Pectoris, Variant (drug therapy)
• Calcium Channel Blockers (administration & dosage, therapeutic use)
• Clinical Trials as Topic
• Drug Administration Schedule
• Electrocardiography
• Female
• Humans
• Male
• Middle Aged
• Monitoring, Physiologic
• Nifedipine (administration & dosage, analogs & derivatives, therapeutic use)